 PureTech Health plc NASDAQ: PRTC has announced a clinical trial and supply agreement with an affiliate of BeiGene Ltd NASDAQ: BGNE. The partnership will evaluate BeiGenes tislelizumab, in combination with PureTechs LYT-200 for the potential treatment of difficult-to-treat solid tumor indications. 